• Recent meetings with regulators, including MHRA, suggest Corthotec will be able to pursue a preclinical development pathway in 2019, positioning it for clinical trials in 2020.
• Patent filed with UK IPO (P/61974). To be back dated to submission date - and applied across EU. Parallel filing with USPTO.
• UK Innovate grant of £150,000.
• Initial EU grant of £41,000.
• SEIS/EIS approved.